Ask AI
David Planchard

David Planchard, MD, PhD

Gustave Roussy
Head of Thoracic Group
Department of Medical Oncology
Villejuif, France

Explore Activities by David Planchard

Title
Format
Credit Type
Credits
Key Studies in Lung Cancer: Independent Conference Coverage of ESMO 2025

Content Format:

Text Module

Credit Type:

AMA | EBAC®

Credits:

1.50
An Expert’s Guide to ESMO 2025: A Preview of the Top Abstracts

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Highlights of the 2025 European Lung Cancer Congress

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.00
Key Updates in Non-Small-Cell Lung Cancers From the ELCC 2025 Annual Meeting

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Latest Developments and Insights on ADCs for Lung Cancer

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3–Targeted ADCs

Content Format:

Video

Credit Type:

AMA | EBAC®

Credits:

1.50
Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3-Targeted ADCs

Content Format:

Credits Only

Credit Type:

AMA | EBAC®

Credits:

1.50
Expanding the Applicability Beyond HER2m and EGFRm: TROP-2–Targeted ADCs in NSCLC and ADCs in Patients with SCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Mapping TROP-2–Targeted ADCs Into the NSCLC Treatment Landscape

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
TROP-2–Targeted ADCs for NSCLC: ​Integrating a New Therapeutic Option

Content Format:

Video

Credit Type:

AMA | EBAC®

Credits:

1.25
Antibody–Drug Conjugates and the Role of TROP-2 in NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
TROP-2–Targeted ADCs for NSCLC: Integrating a New Therapeutic Option

Content Format:

Credits Only

Credit Type:

AMA | EBAC®

Credits:

1.50
The Potential of Antibody‒Drug Conjugates Targeting CEACAM5 in NSCLC

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Research Focus: Targeting CEACAM5 With Novel Antibody‒Drug Conjugates in Nonsquamous Non-Small-Cell Lung Cancer

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.50
Research Focus: Targeting CEACAM5 With Novel Antibody-Drug Conjugates in Nonsquamous Non-Small-Cell-Lung Cancer

Content Format:

Slideset

Credit Type:

--

Credits:

--
Key Studies in Breast, Gynecologic, Renal Cell, Urothelial, Lung, Hepatobiliary, and Skin Cancers: CCO Independent Conference Highlights of the 2022 ESMO Congress

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.25
An Expert’s Guide to ESMO 2022: A Preview of the Top Abstracts

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Current Status of EGFR Tyrosine Kinase Inhibitor Combination Therapy in the Treatment of Newly Diagnosed EGFR-Mutated Advanced NSCLC

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
First-line Osimertinib for EGFR-Mutated Advanced NSCLC: Barriers to Access and Future Directions

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Content Format:

Podcast

Credit Type:

--

Credits:

--
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Content Format:

Video

Credit Type:

AMA

Credits:

1.00
Express PointsCongress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Activity of ADCs in Clinical Trials for Lung Cancer: Anti–TROP-2/CEACAM/c-Met ADCs

Content Format:

Slideset

Credit Type:

--

Credits:

--